Sanofi to help stabilise supply of key antimalarial
This article was originally published in Scrip
Executive Summary
Sanofi's large-scale production of semi-synthetic artemisinin should help stabilise the supply of and reduce the cost of the key component of the chief malaria treatment: artemisinin-based combination therapies (ACTs).